Beam Therapeutics (BEAM) Other Accumulated Expenses (2020 - 2026)

Beam Therapeutics (BEAM) has reported Other Accumulated Expenses for 7 consecutive years, with $9.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 166.91% year-over-year to $9.2 million; the TTM figure through Mar 2026 stood at $9.2 million (up 166.91% YoY), while the FY2025 annual figure was $2.0 million, down 74.59% from the prior year.
• Other Accumulated Expenses improved to $9.2 million in Q1 2026 per BEAM's latest filing, from $2.0 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $28.6 million in Q4 2023 and bottomed at $2.0 million in Q4 2025.
• Historically, Other Accumulated Expenses has averaged $10.2 million across 5 years, with a median of $7.8 million in 2024.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses soared 212.95% — and 2025, when it slumped 90.49%.
• Beam Therapeutics' Other Accumulated Expenses stood at $12.3 million in 2022, then jumped by 133.58% to $28.6 million in 2023, then slumped by 72.73% to $7.8 million in 2024, then sank by 74.59% to $2.0 million in 2025, then jumped by 361.21% to $9.2 million in 2026.
• Business Quant data shows BEAM's Other Accumulated Expenses at $9.2 million in Q1 2026, $2.0 million in Q4 2025, and $2.7 million in Q3 2025.